Integrating a NF-κB-stimulating “danger” signal into the GRP170-based delivery cargo strongly enhances its immunostimulatory and anti-tumor efficacy, which warrants the future studies of Flagrp170 as a novel immunomodulating agent either alone or combined with conventional treatment modalities (chemotherapy and radiotherapy) to restore anti-tumor immunity in the tumor site to achieve in situ vaccination. This evidence concerns the gene HYOU1 and neoplasm.